Extended Data Fig. 1: Subgroup analyses of progression-free survival based on prior exposure to PARP inhibitors. | Nature Cancer

Extended Data Fig. 1: Subgroup analyses of progression-free survival based on prior exposure to PARP inhibitors.

From: Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial

Extended Data Fig. 1

a, patients who were PARP inhibitor naïve. Number of patients: 145 and 70 in the suvemcitug and placebo groups, respectively. P = 0.0004. b, patients who had received prior PARP inhibitor therapy. Number of patients: 136 and 70 in the suvemcitug and placebo groups, respectively. P < 0.0001.

Source data

Back to article page